Recent Advances in Immunotherapy of Cancer

Dear Colleagues,

Cancer immunotherapy has transformed cancer treatment by leveraging the immune system to identify and eradicate tumors. Advances such as immune checkpoint inhibitors, CAR T-cell therapies, and tumor-infiltrating lymphocyte therapies have significantly enhanced patient outcomes. However, challenges such as treatment resistance, patient heterogeneity, and the increasing incidence of immune-related adverse events (irAEs) continue to pose significant obstacles. A comprehensive understanding and management of irAEs, which can range from mild to life-threatening, has become essential to ensure the safe and effective application of immunotherapies.

Incorporating artificial intelligence (AI) has transformative potential in addressing the challenges associated with cancer treatment. AI-driven approaches enhance precision medicine by optimizing patient selection, identifying biomarkers for treatment response and toxicity, and elucidating the complex dynamics of tumor–immune interactions. Additionally, AI facilitates early detection and management of immune-related adverse events (irAEs) by predicting at-risk patients and personalizing interventions. Furthermore, AI accelerates drug discovery, designs innovative combination therapies, and improves the efficiency of clinical trials.

This Special Issue aims to highlight advancements in cancer immunotherapy, the management of irAEs, and the integration of AI to refine and personalize therapeutic strategies. We invite authors to submit papers on a variety of approaches to propel the field of immunotherapy toward safer, more effective, and tailored cancer treatments.

Dr. Jessica Chacon
Dr. Shrikanth Gadad
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.